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Abstract – Changes to foot-and-mouth disease (FMD) control policies since 2001 mean that emergency
vaccination must be considered more readily as a control measure in the future. Since ﬁeld application of
vaccine for emergency use has only rarely been applied, the effectiveness of single dose administration, as
a control measure in an outbreak situation, is poorly understood. In this review we consider all the available
experimental data from studies utilizing either experimental or readily available, commercially produced
vaccines, in order to assess their likely effectiveness as an additional means of controlling FMD transmission
and spread in an emergency. Overall it is concluded that such vaccines offer an additional and valuable
means of FMD control for both ruminants and pigs. They are able to reduce clinical disease, sub-clinical
infection and excretion and onward transmission of virus. However, to be most effective, vaccination should
be rapidly applied to give maximum opportunity for immunity to develop. We also identify areas for future
research and emphasize the importance of vaccine efﬁcacy studies in providing data for models that can help
to predict the efﬁcacy of differing FMD control strategies.
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1. INTRODUCTION
1.1. Foot-and-mouth disease
Foot-and-mouth disease (FMD) is a highly
contagious disease of domesticated ruminants
and pigs which can also affect a large number
of wildlife species [18]. FMD was the ﬁrst
animal disease attributed to infection by a
virus [41], although the disease itself had been
described as early as the sixteenth century in
Italy [35]. The causal agent of the disease is a
small (25–30nm), icosahedral non-enveloped
RNA virus classiﬁed within the Aphthovirus
genus, as a member of the Picornaviridae
[12, 61]. FMD is a vesicular disease, the
clinical severity of which varies with the strain
of foot-and-mouth disease virus (FMDV), as
well as the infecting dose, the species and
individual susceptibility of the host. Direct
or indirect contact with FMDV infected
animals can result in susceptible animals
becoming diseased or sub-clinically infected.
In ruminants, but not pigs, complete clearance
of virus from the pharynx may be delayed
giving rise to persistently infected carriers.
The main route of virus entry, in natural
infections, is the respiratory tract through
inhalation of airborne virus, although virus
may also gain entry through oral ingestion,
or damaged epithelium [2]. There are seven
immunologically distinct serotypes of FMDV:
O, A, C, SAT (South African Territories) 1,
SAT 2, SAT 3 and Asia 1, and infection (or
vaccination) with one serotype does not confer
immunity to another [16]. Additionally, within
serotype there are subtypes against which
vaccines of the same serotype will fail to fully
protect [53].
Various studies have demonstrated that
infected animals can excrete FMDV shortly
before the development of clinical signs and
that peak excretion occurs around the time of
onset of clinical disease [2]. During the course
of the disease an animal produces virus in
excretions and secretions such as saliva, nasal
and lachrymal ﬂuid, milk, expired breath,
urine and faeces, which results in massive
environmental contamination [2]. FMD can
rapidly spread in susceptible populations
causing severe economic losses to both dairy
and meat producing businesses as a result
of lost fertility, productivity and mortality of
young livestock. However, wider effects on a
country’s ability to trade and export animals
and animal products, and the cost of control
measures to prevent entry or eliminate FMDV
accounts for its main economic impact. It is
the disease most feared by livestock holders
and veterinarians and is an Ofﬁce International
des Epizooties (OIE) listed disease [44]. Not
surprisingly, the issue of control is regarded as
a high priority.
1.2. Historic control measures
Although FMD remains widely distributed
throughout the world and is endemic in
many regions, including parts of Africa,
the Middle East, Asia and South America
(sporadic outbreaks), it has been successfully
eradicated, or prevented from gaining a
foothold, in other areas by a variety of
control strategies [17, 37, 40, 43, 64, 65].
Countries which have traditionally remained
free of the disease, such as Australia,
New Zealand, and Japan, primarily due to
their geographical location, and also North
America, have maintained their freedom by
imposing strict import/quarantine legislation.
Incursion of disease, which has only occurred
very occasionally in some of these countries,
has been dealt with by slaughter of infected
animals and their contacts. The United
Kingdom, Ireland, and Scandinavian countries
in which incursions occurred more regularly,
often on an annual basis, developed a more
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organized control program, and as early as
1892 the UK applied a ‘stamping-out’ policy,
which included not only the slaughter and
destruction of infected animals and their
immediate contacts, but thorough cleaning
and disinfection. Subsequently, restrictions
on movement of susceptible livestock were
also introduced, once an outbreak of FMD
was conﬁrmed, in order to reduce spread of
disease.
Europe and South America, however, were
unable to eradicate FMD without the aid of
vaccination. Up until the 1950’s insufﬁcient
vaccine meant that Europe suffered extensive
epidemics, but as vaccine production was
improved and vaccines became more readily
available, annual programs of vaccination
were implemented, and the disease was
brought under control. In 1985 the Euro-
pean Union (EU) decided to implement a
non-prophylactic vaccination policy, which
was ﬁnally introduced in 1991–1992 and
EU member countries became an FMD free
zone. South America, where vaccination was
also practiced, became disadvantaged as their
status as only ‘FMD free with vaccination’
reduced their export markets in Europe.
Therefore they too imposed programs of
control during the 1990’s which meant that
many southern regions of the continent were
able to eradicate the disease to become FMD
free without the continued use of vacci-
nation. Today vaccines are widely used to
control FMD in endemic areas, but frequently
socio-economic constraints result in inade-
quate vaccination programs which provide
incomplete protection and, along with lack
of border and movement controls, allow the
cycle of disease to continue. The limitations
to international policies and the inadequacy
of funds to co-ordinate worldwide control
remain major hurdles which hamper progress
towards global eradication of the disease, but
planning continues toward progressive control
of FMD worldwide [56].
1.3. Rationale for emergency vaccination
All FMD free countries need to be contin-
ually on their guard against re-introduction of
FMDV and have control measures ready that
will reduce transmission and aid rapid elim-
ination of the virus from an area where an
outbreak occurs. The implementation of non-
vaccination policies for the control of FMD
has resulted in domestic livestock populations
which are highly susceptible to the disease
(as evidenced by the 2001 epidemic in the
UK, which spread to Northern Ireland, France
and the Netherlands; the 2000-2001 South
American outbreaks and the 2007 UK out-
break). Current policy for outbreaks of FMD
in many disease-free countries is based upon
total slaughter, disposal, movement restric-
tions and disinfection (‘stamping out’). How-
ever, within the EU, there is provision to resort
to emergency vaccination, particularly should
it be considered likely that the outbreak would
become extensive, or the logistics of slaugh-
tering a large number of animals are unattain-
able. However, some concerns remain over the
effectiveness of emergency vaccination to con-
trol FMD, as questions such as: How fast will
protection be achieved? How long will immu-
nity last? Will transmission be reduced? Will
persistence go undetected? remain to be fully
answered. Additionally, there is often debate
over whether the use of emergency vaccina-
tion would complicate and delay the regaining
of FMD free status which is of great economic
importance.
The primary objectives of this review
are to draw together available experimental
data relating to efﬁcacy of vaccines for
emergency use, particularly with regard to
providing early protection from disease, sub-
clinical infection and onward transmission of
virus. Studies using cattle, sheep and pigs
are considered. We also identify areas for
future research and emphasize the importance
of vaccine efﬁcacy studies in providing
data which inform models that help to
predict the efﬁcacy of differing FMD control
strategies. Speciﬁcally, the review will focus
on readily available commercially produced
FMD vaccines prepared for emergency use
from highly concentrated antigen stored over
liquid nitrogen. However, reference will be
made on occasion to studies which have used
experimental vaccines, including the use of
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novel oil adjuvants or where antigen payload
wasincreasedasameansofimprovingvaccine
performance.
2. EFFICACY OF FMD VACCINES TO
PROTECT AGAINST CLINICAL DISEASE
IN ANIMALS EXPERIMENTALLY
CHALLENGED WITH UNVACCINATED
FMDV INFECTED DONOR ANIMALS
2.1. Emergency vaccination
The deﬁnition of emergency vaccination,
in its broadest sense, is the use of vaccines
to control an outbreak of FMD in a country,
or area, normally free from the disease, in
which routine prophylactic vaccination is not
practiced. However, occasionally emergency
vaccination may also be applied to outbreaks
in countries in which vaccine is routinely
used, to either boost existing immunity or
provide protection against a different serotype,
or strain. In the opinion of the authors, an
ideal emergency vaccine should have the
following characteristics: contain no residual
live FMDV and have minimal side effects in
adultandnewbornanimals;rapidlypreventthe
spread of infection after a single application
with minimal dosage; be compatible with
serological tests that identify infection in
vaccinated animals; be stable under storage
once formulated; provide a broad spectrum of
antigenic protection; and induce a reasonably
long lasting immunity.
Although initially vaccines for emergency
use were bulk reserves of formulated vaccine,
the development of ultra cold storage of con-
centrated antigens, which can be speciﬁcally
formulated into vaccine, as and when required,
has become the more accepted strategy, and
has lead to the establishment of national or
shared antigen banks [6]. Vaccines prepared
fromsuchstoresareusuallyformulatedtocon-
tain higher levels of antigen than conventional
prophylactic vaccines, and as a consequence
are expected, or shown, to be more potent, pro-
viding more rapid immunity and better cross
protection within serotype. Emergency vac-
cines are generally required to achieve a min-
imum potency, PD50 (50% protective dose)
of 6, whereas vaccines for prophylactic use are
often formulated to at least a potency of 3PD50
[34]. In reality, both types of vaccine, when
produced from reputable manufacturers and
banks, are usually formulated to provide PD50
values greatly above the minimum stipulated
value, (where PD50 is deﬁned as the factor by
which the antigen dose may be reduced such
that 50% of the vaccinated animals would be
protected). The lack of precision and inherent
variability associated with biological potency
assay procedures, however, should always be
borne in mind [24,55].
When the concept of emergency vaccina-
tion was originally considered for contingency
use, as a control measure for FMD, very little
was known about how well, or rapidly, FMD
vaccines would protect cattle, pigs and sheep
from disease following a single administra-
tion. For prophylactic use the usual regime is
an initial shot followed by a booster around
4 to 6 weeks later, which is subsequently
followed by further boosts every 4–6 months
or annually depending upon the species, life
expectancy, worth of the animal and prevail-
ing epidemiological conditions [28]. Clearly,
such a regime, developed as a consequence
of years of ﬁeld use, allows sufﬁcient time
for the immune response to develop and be
maintained before encounter with virus [26].
However, experience of using emergency
vaccination is much less than for prophylactic
vaccination, and emergency vaccinated ani-
mals may be challenged soon after a single
immunization; hence experimental work was
necessary to investigate the rapidity of protec-
tion conferred by vaccines used in this way.
2.2. Vaccine studies demonstrating protection
against clinical disease using indirect
contact challenge
Early work from the late 1960’s to 1980’s
in cattle, pigs and occasionally sheep, that
contained high concentrations of FMDV
antigen, showed that it was possible to
protect all three species from typical FMD
lesions on mouth and feet early after a
single immunisation (Tabs. I to III) [29, 36,
38, 59]. Several more studies, carried out
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during the 1990’s, using vaccines prepared
from antigens held as part of the emergency
reserve in the International FMD Vaccine
Bank (IVB) at the Institute for Animal Health,
Pirbright Laboratory, and an indirect aerosol
challenge from infected pigs, conﬁrmed
that higher potency vaccines could protect
cattle and pigs from clinical disease at
2 (strain Asia 1 India) to 4 (strains O1
Lausanne and C1 Oberbayern) days and 4
(strain C1 Oberbayern) days post vaccination
respectively (Tabs. I and II) [25, 57]1.A t
the time of these later studies it became
apparent that sheep and other small ruminants
were involved in most of the outbreaks in
and around the EU member states [5] and
that in an emergency situation it might be
necessary to also vaccinate these species.
Since historically, sheep and goats were not
normally included in vaccination programs,
more information on vaccine efﬁcacy was
required in these species. Hence a series
of experiments using emergency monovalent
FMD vaccines, incorporating either serotype
O1 Lausanne, Asia 1 India and C1 Oberbayern
from the IVB reserve, were undertaken to
investigate early protection in sheep [19]2.
Since sheep are generally less prone to the
clinical manifestations of FMD, the absence
of viraemia was also considered as an
indicator of protection. It was concluded
that emergency vaccines, previously shown
to be effective in eliciting early protection
in cattle and pigs, could perform equally
well in sheep, as they were protected as
1 Salt J.S., Williams L., Statham R., Barnett P.V.,
Further studies on the rate of development of
protection in cattle given emergency vaccination
against FMD, Rep. Session Res. Group Stand-
ing Techn. Comm. Eur. Comm. Contr. FMD,
Moeldling, Denmark, FAO, Rome, 1995, Appendix
17, pp. 90–97.
2 Cox S.J., Dani P., Salt J.S., Barnett P.V., Effect
of emergency vaccines on local virus replication
and virus persistence in sheep using two different
adjuvant formulations, Rep. Session Res. Group
Standing Techn. Comm. Eur. Comm. Contr. FMD,
Pirbright, UK, FAO, Rome, 1998, Appendix 17,
pp. 139–143.
early as 3 (strain O1 Lausanne) or 4 days
post vaccination (strains Asia 1 India and
C1 Oberbayern) (Tab. III). Protection was
further demonstrated by a later experiment
using larger groups of sheep which had been
vaccinated 14 days before FMDV challenge
with O1 Lausanne (Tab. III) [10]. More recent
work using sheep that had been vaccinated
10 and 4 days prior to a semi-heterologous,
9h indirect aerosol challenge from pigs,
conﬁrmed protection against clinical disease
but showed that not all animals were protected
from generalization of FMD, as some became
viraemic (Tab. III) [52].
2.3. Vaccine studies demonstrating protection
against clinical disease using direct contact
challenge
The previously mentioned studies with
emergency vaccines, prepared from antigen
concentrates held over liquid nitrogen, have
nearly all involved indirect aerosol challenge,
to simulate a situation in which infected
premises could infect a neighbouring farm
through windborne spread. This along with
indirect spread via fomites are thought to
be the most likely methods for the spread
of FMDV between farms once movement
restrictions are in place, but fomite spread is
difﬁcult to model experimentally. Suppressive
vaccination, as used in the Netherlands during
2001, where emergency vaccination is applied
around and within the disease foci as a
supplementary control measure to further
dampen down virus excretion, has received
more consideration in recent years. A number
of experiments have examined the efﬁcacy
of emergency vaccines against direct contact
challenge, as if vaccination is applied within
an infected area, there could be the likelihood
that some animals may already be incubating
disease on a farm, and therefore be able to
directly challenge other animals. An initial
study [7] using an O1 Lausanne oil formulated
vaccine, in which groups of three pigs were
immunized at 6, 5 and 4 days prior to a
direct homologous FMDV challenge from two
infected pigs for 2h, showed that all but one
pig in the four day group and one in the six
P a g e8o f3 0( page number not for citation purpose)Review FMD emergency vaccines Vet. Res. (2009) 40:13
day group developed clinical disease (Tab. II).
More recently, published work using a larger
number of pigs, investigating the efﬁcacy of
emergency vaccines against a more severe
semi-heterologous direct contact challenge of
9h, has shown that protection from clinical
disease is difﬁcult to achieve at 10 days post
vaccination, as only 19% of the group were
protected (Tab. II) [51]. However, protection
was greatly improved by extending the time
period between vaccination and challenge
to 29 days, where 75% remained healthy.
Likewise, similar work with vaccinated cattle,
using a ﬁve day direct contact challenge from
ﬁve infected cattle, has shown that following
a 21 day vaccine-to-challenge interval, with
either single strength or 10× antigen payload,
all cattle were protected from disease (Tab. I)
[21,22]. However, when a shorter time period
of 10 days between vaccination and challenge
was used, protection was only achieved in
70–75% of the group, although disease in
the unprotected animals was less severe than
in unvaccinated controls receiving the same
challenge [23]. As far as the authors are aware,
no similar experiments have been carried out
using sheep.
3. EFFICACY OF FMD VACCINES TO
PROTECT AGAINST SUB-CLINICAL
INFECTION, REDUCE VIRUS
EXCRETION AND PERSISTENCE IN
ANIMALS EXPERIMENTALLY
CHALLENGED WITH UNVACCINATED
FMDV INFECTED DONOR ANIMALS
3.1. Prevention of sub-clinical infection, virus
excretion and persistence in cattle
Clearly it is advantageous if a vaccine
protects not only against clinical disease but
also sub-clinical infection, as the likelihood of
disease transmission will thereby be reduced
or indeed eliminated. Results from early
studies frequently indicate that FMD vaccines
which are able to protect from clinical disease
are unable to provide sterile immunity (i.e.,
prevent sub-clinical infection) although there
are occasions, periodically or consistently,
when no virus is recovered from some
animals [29,42,60,62]3; although it should be
emphasized that animals were sometimes only
sampled once or twice during these studies.
Further, it was not fully investigated in these
experiments whether increasing the antigen
content in the vaccine or the time period
between vaccination and challenge could
further reduce sub-clinical infection. The
series of previously described experiments
in cattle carried out by the IVB in the
1990’s [25], using vaccines prepared from
the antigens held in its emergency reserve
was undertaken to address these issues more
comprehensively by examining oropharyngeal
ﬂuid samples collected by probang cup [63]
and the data from these experiments are
summarised in Table IV. Studies with O1
Lausanne suggested that the shorter the period
between vaccination and challenge the more
likely that virus was recovered, although virus
was recovered from all animals, in all groups,
on at least one occasion. Previously, it was
concluded that use of the aqueous vaccine
formulation appeared to be more effective
at reducing the levels of virus recovery [9],
but on re-examination of the data for this
review, the variability at different time points
for both aqueous and oil adjuvants and the
small group size suggests that this conclusion
was not justiﬁed. Re-vaccination of the same
animals, approximately four months later,
with C1 Oberbayern resulted in far fewer
animals locally replicating virus, regardless of
adjuvant. This may have been related to a
difference in the strains ability to establish a
sub-clinical infection, and/or higher potency
of the C1 Oberbayern vaccine, and/or the
result of pre-existing immunity to the previous
vaccine. Hence, a comparison with the O1
Lausanne data is not really possible. A further
study was performed using Asia 1 India,
in which cattle were vaccinated at intervals
between 2 and 12 days prior to challenge. The
results from this experiment were similar to
those of the earlier O1 Lausanne vaccination
3 Garland A.J.M., The inhibitory activity of secre-
tions in cattle against foot-and-mouth disease virus,
Ph.D. thesis, University of London, UK, 1974.
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experiment, as virus was recovered from all
groups of vaccinated cattle (except the 12
days pre-challenge aqueous group). This study
also supported the previous observation from
the O1 Lausanne study, that the longer the
period between vaccination and challenge the
less likely virus was recovered and fewer
the animals that become persistently infected.
More recent studies at IAH Pirbright in cattle,
to assess the efﬁcacy of a high potency
O1 Manisa oil formulated vaccine applied
21 days prior to a direct contact challenge
from infected cattle against both clinical
disease and sub-clinical infection using larger
group size, have shown more conclusively
that vaccination greatly reduces the amount
of virus recovered from vaccinated cattle
as compared to unvaccinated cattle, both in
terms of numbers of animals from which
virus was recovered and the quantity of
virus recovered from infected animals [21].
This was particularly true during the early
post-exposure period during which 100–1000
times more viral RNA was recovered from
unvaccinated cattle. Increasing the antigen
payload of this vaccine ten-fold resulted in
even less virus recovery and less persistently
infected animals (if recovery of viral RNA was
also used as a measure of persistence [22]).
These studies have recently been repeated with
an interval of 10 days between immunization
and challenge, and although no signiﬁcant
difference was identiﬁed between vaccinated
and unvaccinated cattle with regard to the
numbers of cattle sub-clinically infected, a
difference in actual quantity of virus recovered
shortly after challenge was still apparent, with
10–150 times less viral RNA recovered from a
vaccinated animal [23].
Data from these recent O1 Manisa cattle
experiments [21–23] are also summarized in
Table IV, including non-structural antibody
results from each of these experiments, in
order to allow comparison with the earlier
work. Techniques for analyzing samples and
determining status of individual cattle have
moved on since this early work, and the use
ofquantitativeRT-PCRforestimatinglevelsof
viral replication and ELISA’s for nonstructural
antibody seroconversion allow more accurate
assessment of vaccine efﬁcacy than in the
past with regard to sub-clinical infection. For
example, it appears from the O1 Manisa cattle
work [21–23], that non-structural antibody
development correlates with the extent of virus
replicationandthusoffersareliablealternative
to virus isolation from oropharyngeal ﬂuid,
which can provide inconsistent results, both
from a single sample or over a set of time
course samples from an individual animal. The
availability of quantitative RT-PCR, which
is more rapid and less labour intensive
than cell culture titration, also permits more
precise discrimination between levels of
virus replication in individual and groups of
animals [21–23]. Despite the direct challenge
being more severe than used previously, the
resultsindicate that vaccination willreduce the
number of sub-clinically infected animals.
Clinically affected and sub-clinically
infected animals have the potential to become
persistently infected, and although the role
of persistence in the epidemiology of FMD
has not been proven, any reduction in both,
as a result of vaccination, is likely to reduce
the number of persistently infected animals
and the subsequent possibility of transmission
from them. Since clinically diseased animals
are more likely to be recognized and removed,
vaccinated sub-clinically infected animals
potentially pose more of a problem. The O1
Manisa experiments have monitored cattle
up to and beyond 28 days post challenge to
assess the effect of emergency vaccination on
reducing persistence [21–23]. The four week
post challenge data in Table IV shows the
number of persistently infected cattle in each
experiment. Although a trend was identiﬁed
from the early IVB cattle work [25]1 that
less animals became persistently infected the
longer the period between vaccination and
challenge, the small group sizes and variabil-
ity of data makes this difﬁcult to substantiate.
The virus isolation results from the more
recent studies [21–23] in which challenge
occurred at 21 and 10 days post immunization
do appear to conﬁrm this trend, as FMDV
was recovered from 5% of cattle vaccinated
21 days before challenge and 50% of cattle
vaccinated 10 days before challenge, using
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single strength vaccine. Similar differences
were also seen for the 10-fold antigen payload
vaccine. However, if virus isolation and/or
viral RNA recovery are used collectively
as an indicator of persistence, a slightly
different picture emerges, and a lower level
of persistence is then only seen in the cattle
receiving a 10-fold antigen payload vaccine 21
days before challenge. Although the observed
levels of persistence are toward the upper
levels quoted in FMD literature, the true level
of persistence from a severe direct contact
challenge could be as high as 75% of infected,
vaccinated animals. It might be extrapolated,
however, that a less severe challenge will
result in a lower level of persistence and it is
still to be resolved whether detection of viral
RNA without equivalent detection of live virus
at 28 days post challenge and beyond should
be considered as evidence of persistence.
3.2. Prevention of sub-clinical infection, virus
replication and persistence in sheep
A single experiment in which sheep were
vaccinated with large doses of a monovalent
type O BFS 1860 vaccine followed by indirect
contact exposure to infectious pigs for 2h
showed that local virus replication in the
oropharynx was not prevented [36]. However,
since the fully formulated vaccine used in this
study had been stored at 4 ◦C for 10 months
before use it might have deteriorated such that
efﬁcacy would not have been as good as that
conferred by newly prepared vaccine. More
recent early protection studies in sheep [19]2,
using freshly prepared vaccine, afforded the
opportunity toinvestigate the effect of aqueous
and oil formulated emergency vaccines on
sub-clinical infection [19] and results from
these experiments are summarized in Table V.
Bothoilandaqueousmonovalent formulations
of O1 Lausanne and C1 Oberbayern seemed
to reduce the frequency of sub-clinical
infection when monitored up to 28 days
post challenge. All sheep vaccinated at least
7 days before challenge remained free of
virus in the oesophageal-pharyngeal tract
throughout the trials. However, in the study,
using oil adjuvanted Asia 1 India vaccine [19],
virus was recovered from sheep vaccinated
6 and 10 days before challenge, which,
along with the cattle data above, suggests
that it might be more difﬁcult to protect
against sub-clinical infection by this serotype.
The data generated from the use of both
O1 Lausanne and C1 Oberbayern aqueous
and oil formulated vaccines partly supported
the previous observations in cattle that the
earlier the vaccine is administered before
challenge, the more effectively the sub-clinical
infection will be prevented. As observed
for cattle, there was also no tendency
toward either vaccine formulation being more
effective than the other at reducing sub-
clinical infection. In another study [52], in
which sheep were vaccinated with an O1
Manisa oil vaccine, either 10 or 4 days
before challenge with O1 UKG, the notion
that vaccination considerably reduces sub-
clinical infection is also supported (Tab. V).
This study also showed that seroconversion to
nonstructural proteins was weak and transient
in sheep in which virus replication was of
low level or short duration and that the earlier
the vaccine is administered before challenge
the more effectively virus replication is
reduced [52]. In all the experiments reviewed,
viral persistence (at 4 weeks or beyond) was
less in the vaccinated animals compared to the
unvaccinated sheep.
3.3. Inﬂuence of antigen payload on sub-clinical
infection, virus replication and persistence
in sheep
Antigen concentration (payload) per vac-
cine dose can be increased in order to achieve
higher potency vaccine. Since potency tests
measure protection in terms of their ability
to prevent generalization of disease from
the site of inoculation and do not consider
sub-clinical infection, there was little data
available on whether increasing antigen pay-
load can decrease local virus replication. An
experiment carried out in sheep, was designed
speciﬁcally to investigate the effect of antigen
payload on local virus replication. Single
administrations of either a high, medium or
low antigen payload O1 Lausanne vaccine
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were assessed for their ability to protect
groups of seven sheep and reduce local virus
replication and excretion from the oropharynx
following indirect aerosol challenge at 14 days
post immunization [10]. Seven unvaccinated
sheep in this experiment showed signs of clin-
ical FMD, whereas all the vaccinated sheep,
regardless of antigen payload, were protected
against clinical disease and development of
viraemia. Virological and serological results
conﬁrmed that there had been no local virus
replication in the oropharynx of the sheep
from the highest antigen payload vaccine
group in contrast to moderate or substantial
virus replication in the oropharynx of the low-
est payload or unvaccinated group of sheep
respectively (Tab. V). Sero-conversion against
non-structural proteins was also evident in
the lowest antigen payload and unvaccinated
groups. This was the ﬁrst experiment to clearly
show that higher antigen payload vaccines are
capable of inhibiting local virus replication
and the consequential persistent infection
and carrier state in this target species. The
vaccines showed no evidence of promoting a
local mucosal antibody response at the time
of challenge but were capable of stimulating a
systemic interferon gamma response, the level
of which appeared to be related to antigen
payload. The magnitude of response and num-
ber of animals having measurable levels of
interferon gamma certainly decreased as anti-
gen payload was reduced. It was concluded
that this systemic interferon gamma response
could be a useful indicator of the ability of an
FMD vaccine to inhibit local virus replication,
warranting further investigation.
3.4. Prevention of sub-clinical infection and
virus excretion in pigs
Less work has been carried out in pigs
to examine the effect of vaccination on local
virus replication in the absence of clini-
cal signs (sub-clinical infection), most likely
because they are not known to become per-
sistently infected carriers. However, since pigs
are recognized as ‘ampliﬁers’ of FMDV [58]
any reduction in local virus replication at the
acute phase, would be beneﬁcial in the control
of the disease. For the purpose of this section
virus excretion is taken as being representative
of local virus replication having occurred.
A signiﬁcant reduction in airborne virus
recovery from groups of pigs, as measured
by sampling the air of looseboxes, was
achieved when they were vaccinated prior to
challenge, although a single immunization did
not prevent clinical disease in most pigs [60].
Likewise, Salt et al. [57] made no attempt
to evaluate sub-clinical infection in individual
pigs following vaccination with high potency
vaccine, preferring to measure levels of
excretion per group of pigs in isolation
boxes and assess transmission to naïve in-
contacts (see Sect. 4). It was concluded that
protective immunization resulted in reduced
virus excretion. An experiment carried out
by Davidson4, the ﬁrst to assess airborne
recovery from individual pigs, conﬁrmed that
vaccination with a high potency oil adjuvanted
O1 Lausanne vaccine, at either 7 or 21 days
prior to direct contact with infected pigs for
16h, could result in no virus recovery from
some animals (after removal of infected donor
animals) (Tab. VI) but concluded that the
vaccine could not effectively prevent local
virus replication and airborne virus emissions
in all situations. However, it was also noted
that after the ﬁrst 24h, the highest airborne
recovery from sub-clinically infected pigs was
signiﬁcantly lower than peak recoveries from
diseased pigs (P<0.05). A further study
was designed to investigate protection from
direct contact challenge 4, 5 and 6 days
post vaccination. This experiment considered
detection of FMDV from both nasal swab
material of the individual animals and via
HEPEs buffered Eagles medium in air exposed
Petri dishes within each animal box housing
the different vaccination groups. This showed
that a high potency O1 Lausanne vaccine was
unable to prevent local virus replication at
such short intervals between vaccination and
challenge [7]. However, the excreted virus
titres determined from each isolation box were
4 Davidson F.L., Alternative strategies for foot-
and-mouth disease control in pigs, Ph.D. thesis,
University of Hertfordshire, UK, 1997.
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Table VI. Airborne virus recovery from vaccinated pigs following direct contact challenge with infected
pigs.
Animal Days vaccinated Disease Airborne virus recovery (log10TCID50 r e c o v e r e di n1 5m i n )
ref. before exposure 2h 16 h Day 1 Day 2 Day 3 Day 4 Day 5 Day 6
SP 20 7 No 5.5 2.9 Neg Neg Neg Neg Neg Neg
SP 21 7 No 4.2 2.9 2.4 Neg Neg Neg Neg Neg
SP 76 7 No 3.7 3.7 1.9 Neg Neg 2.2 Neg Neg
SP 77 7 No 3.6 2.4 Neg Neg 2.0 2.2 Neg Neg
SP 33 21 No 3.4 Neg Neg Neg Neg Neg Neg Neg
SP 35 21 No 3.9 2.4 Neg 2.2 2.2 2.0 1.9 Neg
SP 78 21 Yes 4.5 Neg Neg 4.2 4.7 3.9 Neg Neg
SP 79 21 No 3.7 2.4 Neg Neg Neg Neg Neg Neg
SP 67 0 No 3.7 2.2 2.2 2.2 2.2 2.2 1.9 1.9
SP 80 0 Yes 3.9 2.4 1.9 4.7 5.9 Died – –
The shaded area denotes the presence of the donor pig.
reduced by 90–98% when compared with
the box holding the infected non-vaccinated
control animals. A more recent study [30],
designed more speciﬁcally to investigate with-
inpentransmission(seeSect.4),demonstrated
that local virus replication, as measured
by virus recovery from oropharyngeal ﬂuid
collected by cotton mouth swabs, could be
prevented in pigs vaccinated 14 days prior to
infection, but not in those vaccinated 7 days
prior to infection. Another recent study [51],
however, using a semi-heterologous, direct
contact challenge at 10 and 29 days post
vaccinationshowedthatalthoughhighpotency
vaccine was unable to prevent sub-clinical
infection, as all vaccinated pigs appeared to
have become infected to some degree, the
vaccine was able to reduce virus replication
and excretion, which could be correlated to the
severity of clinical disease.
4. EFFECT OF FMD VACCINES ON
PREVENTING FMDV TRANSMISSION
TO NAIVE AND VACCINATED ANIMALS
FROM EXPERIMENTALLY
CHALLENGED ANIMALS
4.1. Transmission from vaccinated to naïve,
in-contact animals
The use of emergency vaccination during
an outbreak, or epidemic, is primarily to
reduce transmission, however, few studies
have been designed to speciﬁcally investigate
transmission of FMDV from vaccinated
animals. Donaldson and Kitching [29], using
a monovalent O1 BFS 1860 FMD vaccine
with an estimated potency of 19 PD50 assessed
transmission to naïve cattle from cattle
vaccinated between four and 21 days prior to
challenge (Tab. VII). All 18 cattle, vaccinated
21 days before challenge, remained free from
clinical disease and although four were shown
to be sub-clinically infected, there was no
transmission to in-contact susceptible cattle.
One of the two groups of cattle, vaccinated
14 days prior to challenge, transmitted
sub-clinical infection, but not disease, to
susceptible animals housed with them from
the day after challenge. Shorter periods of
either 4 or 7 days between vaccination and
challenge resulted in transmission of disease
from clinically normal vaccinated to in-
contact animals in 1 of the 2 experiments.
The additional challenge presented by these
diseased in-contact animals then overwhelmed
the immunity of the vaccinated animals.
Subsequent disease was, however, less severe
in these animals and lesions only occurred
in the head region. The authors concluded
that during emergency vaccination programs
it would be advisable to vaccinate all FMD
susceptible animals within the vaccination
zone and that at the boundary of the zone
the vaccinated animals should be kept separate
from unvaccinated animals for at least three
weeks.
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Table VII. Summary table to show transmission from vaccinated or unvaccinated animals to naïve, in
contact animals.
Donor Recipient
Days Clinical disease Clinical
Species Vaccine Challenge vaccinated and/or virus Contact disease Reference
before recovery after began and/or virus
exposure challenge recovery
21 0/3a 1b 0/2
21 0/3 7 0/2
21 0/3 23 0/2
21 0/3 1 0/2
O1 BFS Homologous 21 1/3 1 0/2
1860 indirect 21 3/3 7 0/2
Cattle 10 g/dose aerosol from 2 14 0/3 1 2/2 [29]
Aqueous donor pigs 14 2/3 1 0/2
for1h 7 0/3 1 1/2
73 / 3 1 2 / 2
40 / 3 1 2 / 2
43 / 3 1 2 / 2
0 12/12 1 8/8
C1 Homologous 7 0/3 1 0/2
Oberbayern indirect 5 2/3 1 2/2
2.9g/dose aerosol from 3 4 2/3 1 2/2 [57]
Oil donor pigs for 3 3/3 1 2/2
Pigs 4h 2 3/3 1 2/2
02 / 2 1 2 / 2
O1 Homologous 6 3/3 1 2/2
Lausanne direct contact 5 3/3 1 2/2 [7]
6.1 g/dose with 3 pigs for 4 3/3 1 2/2
Oil 2h 0 3/3 1 2/2
Asia 1 10 2/3 1 1/2
India Homologous 6 2/3 1 1/2
5.25 indirect 4 0/3 1 0/2
g/dose Aerosol from 3 3 0/3 1 1/2
Oil pigs for 4h 0 3/3 1 2/2
Sheep [19]
11 0/3 1 0/2
C1 Homologous 7 0/3 1 0/2
Oberbayern indirect 5 1/3 1 0/2
1.4 g/dose Aerosol from 3 4 0/3 1 0/2
Aqueous pigs for 4h 0 2/3 1 2/2
a Number of animals clinically diseased or from which virus recovered/total number of animals, b number of days
after vaccinated animals challenged.
A similar study using pigs was performed
during the 1990’s and showed that immuniza-
tion at seven days prior to challenge prevented
clinical disease, reduced airborne excretion
of FMDV and prevented contact transmission
to susceptible in-contact pigs (Tab. VII) [57].
As with cattle, pigs vaccinated only four days
before challenge, although protected from
clinical disease, were shown to be capable of
transmitting FMDV to in-contact susceptible
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pigs, which then excreted sufﬁcient FMDV
to cause foot lesion development in two of
the vaccinated pigs, although these lesions
were considered primary in nature. Again,
it was concluded that vaccinated animals
should not be mixed with susceptible animals
for at least seven days after vaccination to
prevent transmission of infection. A more
recent study using pigs vaccinated 4, 5 and 6
days before direct contact challenge showed
transmission of FMDV to all susceptible
in-contact pigs despite the levels of virus
excretion being reduced, as compared with the
levels of FMDV excreted from the infected
unvaccinated controls (Tab. VII) [7]. This
was perhaps to be expected, since most of the
vaccinated pigs also exhibited clinical disease.
However, since pigs pose the main threat of
ampliﬁcation and rapid dissemination of air-
borne FMDV, these results provided evidence
that vaccination within an infected area (sup-
pressive vaccination), to reduce the amount of
virus circulating, might be a useful aid to con-
trolling airborne spread during an outbreak.
This dampening down of virus excretion could
be particularly useful in areas of high pig
density, where the logistics of mass slaughter
and disposal of carcasses might prove difﬁcult.
Likewise, some of the previously men-
tioned vaccine studies on sheep investigated
transmission of FMDV to naïve in-contact
sheep from animals vaccinated at different
times before challenge [19]. Studies using an
oil formulated Asia 1 India vaccine demon-
strated transmission to in-contact sheep from
animals vaccinated at 10, 6 and 3 days before
challenge, where as use of both oil and aque-
ous formulated C1 Oberbayern vaccines pre-
vented transmission to in-contacts, even in the
group where one vaccinated animal was con-
sistently shown to be sub-clinically infected
(Tab. VII). It was concluded that these higher
potency vaccines could reduce, but not totally
prevent, contact transmission.
4.2. Transmission between homogeneously
treated groups of animals
More recent studies carried out in The
Netherlands have attempted to quantify the
reduction of transmission of FMDV. This has
been done by estimating the reproduction ratio
R (i.e., the average number of secondary
cases caused by one infectious animal in
a susceptible population) and/or alternatively
the daily transmission rate,  and the
infectious period T, for different intervals
between vaccination and FMDV challenge.
These studies differed from those described
earlier in that they considered transmission
fromvaccinatedtovaccinated, orunvaccinated
to unvaccinated animals.
In an initial pig study, in which animals
were allowed direct contact with each other
for 14 days following homologous challenge,
no transmission was observed in the group
vaccinated 14 days before challenge [30]
(Tab. VIII). Virus transmission, however, was
shown to occur within the group vaccinated
7 days before challenge. This, and other
studies, in which both intra-typic heterologous
and homologous vaccination were used 14
days prior to challenge [31] (Tab. VIII) or
where a 4-fold vaccine dose was used 7
days prior to challenge [32] (Tab. VIII),
have been used in meta-analyses to quantify
transmission parameters of FMDV strain O
Taiwan among non-vaccinated and vaccinated
pigs [33]. From these studies it was concluded
that vaccination of pigs would be an effective
tool to reduce the transmission of FMDV
as early as one week post vaccination.
Table IX provides a summary of the estimated
transmission parameters  (calculated using
generalised linear modeling), T (by using
survival analysis) and the reproduction ratio
R. However, these experiments also showed
that intradermal injection of pigs with FMDV,
14 days after vaccination, was not suitable to
start an infection chain, so several additional
experiments were carried out in which
vaccinated pigs were exposed to infected
seeder pigs to calculate similar transmission
parameters (Tabs. VIII and IX) [46]. The
revised transmission design and challenge
method more readily allowed quantiﬁcation
of transmission of FMDV among vaccinated
pigs, but according to this study it was
concluded that a single vaccination was not
sufﬁcient to stop pig to pig virus transmission
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Table VIII. Summary table to show transmission between homogeneously treated groups of animals.
Donor Recipient
Clinical Clinical
Days disease disease
Species Vaccine Challenge vaccinated and/or virus Contact and/or virus Ref.
before recovery after began recovery
exposure challenge
O Taiwan Homologous 14 0/5a 1b 0/5
Pigs 3 g/dose intradermal 7 5/5 1 5/5 [30]
Oil inoculation 0 5/5 1 5/5
O Taiwan Homologous 1
3 g/dose intradermal 14 0/5 0/5
Oil inoculation
O Manisa Heterologous O
Pigs 3 g/dose Taiwan 1 [31]
Oil intradermal 14 0/5 0/5
inoculation
OT a i w a n
intradermal 0 5/5 1 5/5
inoculation
O Taiwan Homologous
3 g/dose intradermal 7 5/5 1 5/5
Oil inoculation
OT a i w a n
4× Homologous
Pigs 3 g/dose intradermal 7 5/5 1 3/5 [36]
Oil inoculation
OT a i w a n
intradermal 0 5/5 1 5/5
inoculation
O1 Manisa O/NET/2001
5 g/dose Continuous 14 4/6 N/A N/A
oil durect contact 0 5/6
(1:1)
Pigs O1 Manisa O/NET/2001 14 (Ac) 5/5 1 5/5 [46]
5 g/dose direct contact 0 (A) 5/5 1 5/5
oil with 4 pigs for 14 (B) 4/5 1 4/5
1day 0 (B) 5/5 1 5/5
0 (A) 2/2
O/NET/2001 0 (B) 2/2
Cattle Continuous 0 (C) 1/2
(calves) direct contact 0 (D) 1/2 N/A N/A [45]
with 2 calves 0 (E) 1/2
0( F ) 2 / 2
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Table VIII. Continued.
Donor Recipient
Clinical Clinical
Days disease disease
Species Vaccine Challenge vaccinated and/or virus Contact and/or virus Ref.
before recovery after began recovery
exposure challenge
14 (A) 1/2
O1 Manisa O/NET/2001 14 (B) 0/2
Oil Continuous 14 (C) 0/2 N/A N/A
11 PD50 direct contact 14 (D) 0/2
with 2 calves 14 (E) 0/2
14 (F) 0/2
O/NET/2001
Continuous 0 (A) 5/5 N/A N/A
direct contact 0 (B) 5/5
Cattle with 5 cattle
(dairy) O1 Manisa O/NET/2001 [47]
Oil Continuous 14 (A) 0/5
9P D 50 direct contact 14 (B) 0/5 N/A N/A
with 5 cattled
0 (A) 1/2
O/NET/2001 0 (B) 0/2
Continuous 0 (C) 0/2 N/A N/A
direct contact 0 (D) 2/2
with 2 lambs 0 (E) 0/2
Sheep 0 (F) 2/2
(lambs) 14 (G) 0/2 [48]
O1 Manisa O/NET/2001 14 (H) 1/2
Oil Continuous 14 (I) 0/2
6P D 50 direct contact 14 (J) 0/2
with 2 lambsd 14 (K) 0/2
14 (L) 0/2
O1 Manisa Semi-
? (18 heterologous 10 7/10 2 1/4
Sheep PD50 for indirect aerosol 4 8/10 2 1/4 [52]
cattle) from 3 infectious 0 8/8 N/A N/A
Oil pigs for 9 h
a Number of animals clinically diseased or from which virus recovered/total number of animals, b number of days
after vaccinated animals challenged, c replicate, d donor animals vaccinated before intranasal inoculation.
within a group of pigs, and that major
outbreaks may still be expected even within
groups of vaccinated pigs, although R was
largely reduced by vaccination.
An experiment with calves was also
performed to determine whether FMDV
could be passed between those with limited
contact, as during the 2001 outbreak in The
Netherlands there appeared to be limited
transmission between animals on two infected
veal-calf farms [13]. The study conﬁrmed
that no transmission of FMDV occurred,
despite recovery of virus from those animals
initially infected. The authors, however,
emphasized, on several occasions, the dangers
of extrapolating results from experiments such
as these, and since R was not signiﬁcantly
below 1 (Tab. IX) suggested that major
outbreaks could not be ruled out, for the
strain O/NET/2001. It was concluded during
this study that it might have been more
logical to allow free mingling of calves,
and hence a follow up study [45] using
both unvaccinated and vaccinated calves was
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undertaken (Tab. VIII). In these experiments
groups of four calves, either vaccinated two
weeks before challenge, or unvaccinated,
were allowed to mingle freely. At the time
of challenge two animals from each group
were inoculated intra-nasally with FMDV
O/NET/2001 and then 20h later reunited with
the other two calves in their group, thereby
subjecting these animals to contact exposure.
FMDV transmission from inoculated animals
to un-inoculated calves occurred in all the non-
vaccinated groups but not to all contact calves.
In the vaccinated groups, virus transmission
was limited to one in-contact calf. The
estimated R values for each group are given
in Table IX, and indicate that vaccination
would be successful as an additional tool to
control transmission of FMDV in an outbreak.
A more recent follow on study, designed to
investigate whether virus transmission is also
signiﬁcantly reduced among adult dairy cattle
following a single application of emergency
vaccine (Tab. VIII) [47], has also concluded
that vaccination is effective in reducing
virus transmission (Tab. IX). A signiﬁcant
difference was shown in virus transmission
in vaccinated and non-vaccinated groups of
lactating cows.
A similar study has also been carried
out in sheep [48] (Tab. VIII). In these
experiments groups of four lambs, either
vaccinated two weeks before challenge or
unvaccinated were allowed to mingle freely.
At the time of challenge, two lambs from
each group were inoculated and the other half
contact exposed to the inoculated animals for
30 days. The estimated R values are given in
Table IX. Virus transmission, as quantiﬁed by
the reproduction ratio R using the ﬁnal size
method, did not differ statistically between
the vaccinated and non-vaccinated groups of
lambs. The data suggested that FMDV can
persist in a sheep population. However, as the
reproduction ratio was only slightly above 1
for unvaccinated animals, it was concluded
that vaccination might only have a small
effect on transmission, in spite of the fact that
virus excretion and duration of virus excretion
was signiﬁcantly reduced after vaccination. In
another study [52], virus transmission from
vaccinated sub-clinically infected sheep to
introduced vaccinated sentinels was shown
not to be sufﬁcient to cause non-structural
protein seroconversion or signiﬁcant virus
shedding (Tab. VIII), and it was concluded that
the spread of infection would be controlled,
even under intensive management conditions,
in ﬂocks which had only recently been
vaccinated 4 days prior to challenge.
5. DURATION OF IMMUNITY FOLLOWING
A SINGLE APPLICATION OF VACCINE
Ideally vaccines should be capable of stim-
ulating a potent long lasting immunity after
a single vaccination and much research effort
has been directed towards improving FMD
vaccines and understanding the host’s immune
responses to natural infection in order to
achievethis(asreviewedby[11,26,27]).How-
ever, depending upon the type and quality, the
often lower potency vaccines applied conven-
tionally for prophylactic use in endemic areas
provide immunity that often lasts no longer
than 4–6 months in the absence of booster
doses. The main requirement of vaccines for
emergency use has been to rapidly induce
protective immunity in animals following a
single shot, as a means of controlling viral
spread. Thus, the main thrust of early research
was directed at assessing how early protection
could be achieved in animals which eventually
would be culled. However, recently there has
been a shift away from control policies that
encompass a vaccinate-to-cull with preference
toward vaccinate-to-live strategies. Conse-
quently, studies to investigate duration of
protective immunity against FMD following a
single application of vaccine in an emergency
will be important in order to provide infor-
mation for dealing with prolonged outbreaks
affecting emergency vaccinated livestock.
Using South African Territories serotype
vaccines, studies in cattle have shown that vac-
cines formulated with either Montanide ISA
25 or ISA 206 oil adjuvants elicited a high
level of antibodies which were maintained for
at least six months [39] whereas another study
in cattle using similar adjuvanted serotype
A24 Cruzeiro vaccines, failed to demonstrate
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a long duration of immunity, as antibody titres
were waning by 43 days post vaccination [4].
Subsequently, a study in sheep (Trial 1), in
which groups of three animals received either
oil or aqueous O1 Manisa or A22 Iraq vac-
cine formulations, showed that following a
single application, the speciﬁc antibody lev-
els against both vaccine strains could remain
high for up to 168 days post vaccination,
particularly where an oil based formulation
was used [20]. Additionally, a recent study
using several oil adjuvanted vaccines contain-
ing either O1 Manisa, A Turkey 14/98 or Asia
1 Shamir has also conﬁrmed durability of the
antibody response for at least 6 months5.T o
date there have been no published experiments
in either cattle or sheep immunized with a sin-
gle dose of higher potency vaccine and then
challenged at a time point beyond 28 days
post vaccination to assess long-term protec-
tion. However, recent work by the authors
using a high potency, oil adjuvanted A22 vac-
cine, in which 20 cattle received a homol-
ogous intradermolingual challenge 6 months
post vaccination, showed that animals were
protected from clinical disease (unpublished
observation). Further experiments are planned
using different FMDV serotypes.
In contrast to the ruminant studies, pigs
have been examined in slightly greater
detail for long-term immunity following a
single immunization with higher potency
vaccine [20]. In groups of three pigs it
was demonstrated that antibody levels were
maintained for up to 218 days. A second
trial, which used groups of four pigs,
included an indirect contact challenge from
pigs infected with C1 Oberbayern. Pigs that
received a homologous challenge at 215 days
post vaccination showed no signs of clinical
disease whereas those animals vaccinated
with the heterologous strain, O1 Lausanne,
showed typical signs of FMD. This indicated
that the required protective immunity against
5 Selman P., Chenard G., Dekker A., Cedivac-FMD:
Durationofimmunityincattle,sheepandpigs,Rep.
Session Res. Group Standing Techn. Comm. Eur.
Comm. Contr. FMD, Paphos, Cyprus, FAO, Rome,
2006, Appendix 31, pp. 215–219.
FMD could be maintained for at least 7
months in this species. The recent study5
also demonstrated that high levels of antibody
were maintained in pigs for at least 6 months
following a single dose of vaccine.
6. GENERAL DISCUSSION
The work reviewed has provided valuable
insight on how efﬁcacious vaccines might
be for emergency use in cattle, sheep and
pigs. There are many variables implicit in
vaccine/challenge studies including relative
strength of vaccine dose, vaccine/challenge
interval and challenge severity, itself depen-
dent on weight, route and match of challenge.
Likewise, measures of outcome/success are
several, including options to measure clini-
cal protection, virus replication/excretion and
virus transmission. The very nature of FMD,
its host range and differences in serotype,
pathogenesis, and modes of transmission com-
plicate study design and make experiments
supposedly simulating ﬁeld scenarios difﬁcult.
The summary tables included in this review
show the variation in experimental design and
exemplify how difﬁcult it is to draw deﬁnitive
conclusions on FMD vaccine efﬁcacy, and in
reality, only broad conclusions can be drawn.
In more recent studies [21–23, 51, 52], there
has been a shift towards using ‘worst case sce-
nario’ involving longer, direct contact chal-
lenges with viruses that are semi-heterologous
to the vaccine strains, with the hope that if a
good result can be obtained then the outcome
of less severe challenge scenarios should at
least be equal if not better.
It is thus difﬁcult to compare experiments
directly, though the data shows that a
single shot of vaccine with relatively high
antigen payload, is capable of protecting all
three species from clinical disease, and that
ruminants will most likely be protected sooner
than pigs. Funding limitations and the expense
of performing large animal experiments in
disease secure isolation facilities have limited
the numbers of animals used in many of the
studies, which makes statistical interpretation
of data difﬁcult. However, it has been possible
to show that challenge dose/duration of
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exposure and the length of time between
vaccination and challenge with FMDV are all
important in determining whether protection
is achieved. For all species, the lighter the
challenge and the longer the period between
vaccination and challenge, the more likely
animals are to be protected, although the
data does suggest that pigs are more difﬁcult
to protect from clinical disease early after
vaccination, once they become infected.
Also important is the prevention of sub-
clinical infection and/or reduction in virus
excretion, which in the absence of clinical
disease could go unnoticed. The experimen-
tal evidence suggests that FMD vaccines, fol-
lowing a single administration, can sometimes
prevent sub-clinical infection in cattle, sheep
and pigs, but usually reduce virus replication
and shedding compared to unvaccinated and
vaccinated but clinically affected animals. As
for clinical protection, the greater the period
between vaccination and challenge and the
less severe the challenge, then the less likely
virus will be recovered. Non structural pro-
tein serology appears to be a useful indica-
tor of the extent of virus replication in sub-
clinically infected animals. Lacking at present
is quantitative data with regard to the effect of
vaccination on reduction of FMDV excretion
in breath. Such information would be particu-
larly useful for pigs, since they are considered
the main ampliﬁers of FMDV and therefore
potentially an important source of airborne
spread.
There has quite rightly also been a shift
away from investigating clinical protection
towards investigation of the ability of FMD
vaccines to reduce transmission, which after
all, is the principle aim of vaccine appli-
cation in an emergency situation. The stud-
ies reviewed suggest that good quality FMD
vaccines are able to reduce transmission from
vaccinated animals to both naïve and vac-
cinated animals when held in direct contact
with each other, although on occasion a sin-
gle vaccination was not sufﬁcient to stop
virus transmission completely, suggesting that
some transmission may still be expected, even
in groups of vaccinated animals. However,
because most results are from within pen
transmission experiments it may be hypoth-
esized that transmission of FMDV between
herds during an outbreak when movement
restrictions are in place, would be less likely
than shown experimentally, since the expo-
sure dose and contact rate between herds
will be reduced. Hence the data strongly sug-
gests that transmission from vaccinated ani-
mals between premises would be extremely
limited. As would be expected, the transmis-
sion data complements the sub-clinical data in
that the greater the period between vaccination
and challenge the less likely transmission was
observed.
More carefully designed transmission
experiments to investigate indirect transmis-
sion are required, along the lines of those
carried out in The Netherlands [30–32,45–48]
particularly with regard to using shorter
intervals between vaccination and challenge
and between species Additionally, retrospec-
tive meta-analyses of the aforementioned
studies not speciﬁcally designed to investigate
transmission within projects, should also be
encouraged. This will provide amongst others,
transmission parameter estimates for use in
FMD modeling exercises, and further assist
policy makers in national governments, the
EU and worldwide on appropriate control
strategies. Particularly useful will be quantify-
ing the reduction in transmission of FMDV by
estimating the reproduction ratio for different
intervals between vaccination and FMDV
infection. The move towards using larger
group sizes in more recent studies has also
enabled not only more statistical analysis
but also provided data more suitable for use
by modelers, for example, a recent paper
to estimate the prevalence of FMD carriers
after reactive vaccination [3]. However, more
consistency in future experimental designs
would further aid subsequent interpretation of
data generated from different experiments.
The closeness of match between the out-
break strain and the vaccine applied will affect
vaccine performance in an emergency situa-
tion, and more recent experimental work has
attempted to also address the issue that out-
breaks will involve isolates not homologous
to the vaccine strain by using heterologous
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challenges [1, 14, 21–23, 31, 45–48]6.I ti s
vitally important to match outbreak strains to
the most appropriate vaccine held in an emer-
gency vaccine bank, and world wide moni-
toring of ﬁeld isolates, and in vitro antigenic
matching studies continue, to ensure the most
appropriate antigen stocks are held [53]. The
potencytestingofsuchstocks,however,gener-
ally involves homologous challenge, so these
experimental studies with heterologous chal-
lenges have provided useful information on
cross-protection following a single immuniza-
tion with vaccine. Arguably in the future, stud-
ies should continue to use heterologous chal-
lenges in order to better represent the ﬁeld
situation.
Morestudiesarerequiredtosubstantiatethe
importance of antigen payload, both in terms
of providing improved protection from sub-
clinical infection and perhaps broader cross
reactivity within serotype, and to further elu-
cidate the immune mechanisms involved in
early protection from both disease and sub-
clinical infection. Nevertheless, it is clear from
completed studies that the presently available
emergencyvaccinesshouldbeusedmoreread-
ily as an additional tool for control of FMD in
cattle, sheep and pigs than they are at present.
Since the 2001 FMD outbreaks in the EU,
in which millions of animals were culled and
destroyed, provoking discussion on the ethics
of a non-vaccination policy, there has been a
subsequent shift in EU policy toward recog-
nizing that emergency vaccination offers an
additional and publicly more acceptable alter-
native. The ﬁndings of many of the studies
reviewed suggest however, that effectiveness
at providing protection from disease and pre-
venting transmission (by reducing or prevent-
ing FMDV excretion), is very much related
to the duration between vaccination and sub-
sequent encounter with FMDV. Therefore, if
6 Srinivasan V.A., Nagendra Kumar S.B., Madhan
M., Mohan V., Maroudam V., Santha Kumar
P., et al., Preliminary results to evaluate cross-
protection between O1 Manisa and O1 Campos in
cattle, Rep. Session Res. Group Standing Techn.
Comm. Eur. Comm. Contr. FMD, Paphos, Cyprus,
FAO, Rome, 2006, Appendix 30, pp. 207–214.
vaccination is to be employed in an outbreak,
the decision to do so must avoid delay, and
thus provide maximum opportunity for immu-
nity to develop. Challenge dose will of course
also be important in determining whether ani-
mals become infected, but continued imposi-
tion of movement restrictions should ensure
most transmission would be limited to indi-
rect methods (low dose) rather than by addi-
tionaldirectcontact.Thedirective2003/85/EC
thus states that all member countries should
have arrangements in place for possible use
of emergency vaccination as soon as FMD is
conﬁrmed. Additionally, in order to support
a ‘vaccination to live’ strategy, the infected
countries disease free status may now be
regained earlier, at six months after the last
vaccination, providing absence of infection
can be demonstrated [44]. Consequently, and
as a priority, work continues to be directed
at developing and evaluating improved assays
for the differentiation of vaccinated-only from
infected animals [15,49,50,54].
Nowadays, not only is information required
on early responses but, owing to the change
in EU policy toward ‘vaccinate-to-live,’ there
is also a need for information on the
duration of the response following a single
immunization. Durability of response has been
a rather neglected area of research, but the
limited studies carried out in sheep and
pigs [20], and the more recent unpublished
work in cattle, suggest that higher potency
oil adjuvanted vaccines promote a longer
lasting response than seen for lower potency
vaccines. Further work is necessary in both
pigs and ruminants to substantiate these
results and conﬁrm that a single application
of vaccine could confer protection for the
average length of an outbreak, avoiding the
need to revaccinate. If longer durability can
be proved, the possibility of using higher
potency vaccines in FMD endemic areas of the
world could be considered in order to reduce
the frequency of vaccine application, perhaps
making eradication by vaccination campaigns
more viable. However, the feasibility of such
a scheme may also be dependent on the
development of more cost effective vaccine
production methods.
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Although the development of novel FMD
vaccines remains high on the agenda for many
FMD laboratories worldwide, as exempliﬁed
by developments in adenovirus vectored vac-
cines, we are still likely to be dependent
on the current inactivated whole viral anti-
gen vaccines for several years. Detailed stud-
ies of the efﬁcacy and optimal dosage for
presently available vaccines, as well as stud-
ies investigating new adjuvants and/or deliv-
ery routes, are essential in support of con-
tingency planning and emergency use. Stud-
ies previously referred to, comparing aqueous
and oil adjuvanted formulations for emergency
use in cattle and sheep, support this notion.
It is clear from these studies that vaccines
formulated with new generation mineral oils
perform equally as well as traditionally used
aluminium hydroxide/saponin formulations in
ruminants, following a single administration.
Hence, this work has demonstrated that in an
outbreak situation a single, oil formulation of
vaccine need only be manufactured and uti-
lized for all three main target species. The
other advantages of using oil adjuvanted vac-
cines are versatility, simplicity of the man-
ufacturing process, and improved shelf-life
compared to aqueous formulated vaccines [4],
with the potential to store for many years in
vaccine banks [8]. Additionally, studies car-
ried out with these vaccines allow further
investigation of the various immune parame-
ters important for protection from disease and
prevention of sub-clinical infection. Immune
defence against virus infection involves both
innate and speciﬁc (adaptive) phases. Histori-
cally, the speciﬁc humoral antibody responses
have been considered the most important fac-
tor conferring protection against FMD, but a
clearer understanding of early cell mediated
responses following vaccination in vivo and
how these correlate with protection is still
required. Such knowledge is an essential pre-
requisite for the optimization of novel vaccine
approaches.
It is hoped that future studies may be
designed to incorporate the aforementioned
areas of interest in order to continue broad-
ening our understanding of how such vaccines
work, and how they can be improved and be
better applied, particularly in an emergency
situation.
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